Search results for " Infectious Diseases"

showing 10 items of 138 documents

Fermented Milk Consumption and Common Infections in Children Attending Day-Care Centers: A Randomized Trial

2016

Supplemental Digital Content is available in the text

MalePediatricsmedicine.medical_specialtyLactobacillus caseiCultured Milk ProductsDay careCommunicable Diseaseslaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialrespiratory infectionlaw030225 pediatricsLactobacillus casei CNCM I-1518Cultured Milk ProductsmedicineAnimalsHumans030212 general & internal medicineChildbiologybusiness.industryIncidenceProbioticsIncidence (epidemiology)rhinopharyngitisOriginal Articles: NutritionGastroenterologyfood and beveragesChild Day Care Centersbiology.organism_classificationClinical trialLacticaseibacillus caseiMilkMulticenter studyCommon infectious diseasesChild PreschoolFermentationPediatrics Perinatology and Child HealthComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemalebusinessLactobacillus caseigastrointestinal infectionJournal of Pediatric Gastroenterology & Nutrition
researchProduct

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

2008

SUMMARYHumoral and cell-mediated immunity (CMI) againstB. pertussiswas assessed in a sample of adolescent, adult and senior subjects distributed in five different geographical areas in Italy. Most (99·1%) subjects had IgG anti-pertussis toxin (PT) antibodies exceeding the minimum detection level [⩾2 ELISA units (EU)/ml]. There were no significant differences between the genders; 6·2% samples recorded titres ⩾100 EU/ml. CMI was positive [stimulation index (SI) ⩾5] against PT in 39·0% of all samples. This study suggests thatB. pertussiscontinues to circulate in age groups that have been previously considered to be uninvolved in the circulation of this pathogen and that adolescent and adult pe…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaCellular immunityBordetella pertussisEpidemiologyWhooping CoughBordetella pertussisSeroepidemiologic StudiesEpidemiology80 and overLymphocytesAged 80 and overeducation.field_of_studybiologyadultBacterialMiddle AgedOriginal PapersAntibodies BacterialseniorInfectious DiseasesB. pertussis Humoral and cell-mediated immunity ELISAItalyFemaleAntibodyAdultmedicine.medical_specialtyBordetella pertussiAdolescent; Adult; Aged; Aged 80 and over; Antibodies Bacterial; Antitoxins; Bordetella pertussis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G; Italy; Lymphocytes; Male; Middle Aged; Seroepidemiologic Studies; Whooping Cough; Epidemiology; Infectious DiseasesAdolescentPopulationEnzyme-Linked Immunosorbent AssayAntibodiesNOImmunitymedicineHumanseducationimmunità cellulo mediataAgedbusiness.industrybiology.organism_classificationadolescentImmunoglobulin GHumoral immunityImmunologyEtiologybiology.proteinimmunità umoraleAntitoxinsbusiness
researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

MaleSettore MED/09 - Medicina Internaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Hepacivirusboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Virology; Infectious DiseasesGastroenterologyIFN-based therapy; boceprevir; cirrhosis; first-generation protease inhibitors; hepatitis Cfirst-generation protease inhibitorchemistry.chemical_compoundLiver diseaseboceprevirMedicineViralChronicSettore MED/12 - Gastroenterologiaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy; Combination; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA; Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Medicine (all)virus diseasesHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CInfectious DiseasesTreatment OutcomeItalyHCVCombinationRNA ViralDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyProlineAlpha interferonInfectious DiseaseAntiviral AgentsDrug TherapyVirologyInternal medicineBoceprevirRibavirinboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis c; IFN-based therapy; adult; aged; antiviral agents; drug therapy combination; female; hepacivirus; hepatitis c chronic; humans; interferon-alpha; italy; male; middle aged; proline; RNA viral; ribavirin; spain; treatment outcome; viral load; hepatology; infectious diseases; virologyHumansDecompensationAdverse effectAgedAntiviral AgentIFN-based therapyHepaciviruHepatologybusiness.industryRibavirincirrhosisInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Loadfirst-generation protease inhibitorschemistrySpainImmunologyRNAbusinesscirrhosi
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

2021

Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231…

MaleVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERinfectious diseases0302 clinical medicine030202 anesthesiologyAnesthesiologyCirugía80 and overProspective StudiesYoung adultChildLungAged 80 and overCOVID-19 ; delay ; SARS-CoV-2 ; surgery ; timingSARS‐CoV‐2 infectionOperativeChild PreschoolPneumonia & InfluenzaInfectionCohort studyHumanmedicine.medical_specialtydelayClinical SciencesSars-cov-2GlobalSurg CollaborativeSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciencesClinical ResearchAnesthesiologyBiodefenseCorrespondence617HumansPULMONARY COMPLICATIONSCRIANÇAS EM IDADE PRÉ-ESCOLARAgedScience & TechnologyCirurgiaPreventionCOVID-19; SARS-CoV-2; delay; surgery; timingInfantOdds ratioPneumoniaProspective StudieClinical research/dk/atira/pure/core/keywords/uob_covid19SurgeryHuman medicine610 Medizin und Gesundheit1109 NeurosciencesInternationalitySettore MED/29 - CHIRURGIA MAXILLOFACCIALESettore MED/18 - CHIRURGIA GENERALECOVID-19; delay; SARS-CoV-2; surgery; timing; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Male; Middle Aged; Prospective Studies; SARS-CoV-2; Surgical Procedures Operative; Time; Young Adult; COVID-19; Internationality; Practice Guidelines as TopicgastroenterologyCohort StudiessurgeryMedicine and Health Sciencestiming030212 general & internal medicineProspective cohort studyMortality rateCOVID-19; delay; SARS-CoV-2; surgery; timingCovid19Middle AgedInfectious DiseasesSurgical Procedures OperativePractice Guidelines as TopicFemalePatient Safetymedicine.symptom6.4 SurgeryLife Sciences & BiomedicineAdult61Adolescent610 Medicine & healthCOVID-19 SARS-CoV-2 delay surgery timingAsymptomaticNOCOVIDSurg CollaborativeTimeVaccine RelatedYoung AdultAll institutes and research themes of the Radboud University Medical CentermedicineMortalitatddc:610MortalityPreschoolLS7_4Surgical Proceduresbusiness.industrySARS-CoV-2NeurosciencesEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologySurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Anesthesiology and Pain MedicineEmerging Infectious DiseasesGood Health and Well BeingMortalidadCohort Studiebusiness
researchProduct

Ticks infesting humans in Italy and associated pathogens

2014

Background: Ticks may transmit a large variety of pathogens, which cause illnesses in animals and humans, commonly referred to as to tick-borne diseases (TBDs). The incidence of human TBDs in Italy is underestimated because of poor surveillance and the scant amount of studies available. Methods. Samples (n = 561) were collected from humans in four main geographical areas of Italy (i.e., northwestern, northeastern, southern Italy, and Sicily), which represent a variety of environments. After being morphologically identified, ticks were molecularly tested with selected protocols for the presence of pathogens of the genera Rickettsia, Babesia, Theileria, Candidatus Neoehrlichia mikurensis, Bor…

MaleVeterinary medicineBorrelia valaisianaSettore MED/17 - Malattie InfettiveRhipicephalus sanguineusInfectious DiseaseDistributionBorrelia afzeliimedicine.disease_causeTicksparasitic diseasesmedicineTick-borne diseasesHumansAnimalsTick-borne diseasebiologyPathogenAnimalMedicine (all)ResearchTick-borne diseasebiology.organism_classificationmedicine.diseaseHaemaphysalisbacterial infections and mycosesTick InfestationTick InfestationsRhipicephalusInfectious DiseasesItalyIxodesParasitologyFemaleDistribution; Humans; Italy; Pathogens; Tick-borne diseases; Ticks; Animals; Female; Humans; Italy; Male; Tick Infestations; Ticks; Parasitology; Infectious Diseases; Medicine (all)PathogensDermacentorHumanTick
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome

2014

Background: Abdominal infections are frequent causes of sepsis and septic shock in the intensive care unit (ICU) and are associated with adverse outcomes. We analyzed the characteristics, treatments and outcome of ICU patients with abdominal infections using data extracted from a one-day point prevalence study, the Extended Prevalence of Infection in the ICU (EPIC) II.Methods: EPIC II included 13,796 adult patients from 1,265 ICUs in 75 countries. Infection was defined using the International Sepsis Forum criteria. Microbiological analyses were performed locally. Participating ICUs provided patient follow-up until hospital discharge or for 60 days.Results: Of the 7,087 infected patients, 1,…

Malehumanoslnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Settore MED/41 - AnestesiologiaGUIDELINESlaw.inventionsepsislawAbdomenabdominal infections; crtitical carePrevalenceMedicine and Health SciencesMedicinePathologie maladies infectieusesAbdomen; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Prevalence; Sepsis; Treatment Outcome; Young Adult; Intensive Care Units; Infectious Diseasesmediana edadMedicine(all)ancianoAbdominal Infection Sepsis Epic IIresultado del tratamientoprevalenciaBacterial InfectionsMiddle AgedadultoAbdominal infectionIntensive care unitAbscessAnti-Bacterial AgentsPREVALENCEadulto jovenIntensive Care UnitsTreatment OutcomeInfectious Diseasesmedicine.anatomical_structureSAPS IIAbdominal infection ; Abscess ; Peritonitis ; Severe sepsis ; Critical care ; Antibiotic therapy ; MicrobiologyFemaleSOFA score10023 Institute of Intensive Care MedicineantibacterianosResearch ArticleAdultmedicine.medical_specialtyCritical Illnessunidades de cuidados intensivosenfermedad críticaPeritonitis610 Medicine & healthNOSOCOMIAL INTRAABDOMINAL INFECTIONSPeritonitisMicrobiologySepsisYoung AdultMORBIDITYInternal medicineMANAGEMENTHumansAgedCANDIDASEPSISbusiness.industrySeptic shockMORTALITYAbdominal InfectionADULTS2725 Infectious DiseasesAntibiotic therapymedicine.diseaseSevere sepsisSurgeryCritical careCross-Sectional Studiesinfecciones bacterianasAbdomenbusinessestudios transversales
researchProduct

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DAL…

2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The followi…

Malevalidityvalidation proceInternational CooperationSettore MED/41 - Anestesiologiadrug protein bindingGastroenterologylaw.inventionPlasmaStaphylococcus infectionCritically ill patientsInterquartile rangelaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntibioticsantibiotic therapyPharmacology (medical)Pharmacology & PharmacyAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical)Antibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoringclinical articleChromatographymedicine.diagnostic_testdrug dose regimencritical illneTeicoplaninHypoalbuminaemiaMedicine (all)articleGlycopeptidesclinical trialGeneral MedicineMiddle Agedtrough time concentrationdrug protein binding variabilityIntensive care unitGlycopeptides Antibiotics Critically ill patients Pharmacokinetics Hypoalbuminaemia ICU3. Good healthAnti-Bacterial Agentsantiinfective agentdrug distributionInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journalmulticenter study (topic)Vancomycinblood samplingFemaleCritically ill patientDrug MonitoringHumanmedicine.drugProtein BindingMicrobiology (medical)Adultmedicine.medical_specialtyhigh performance liquid chromatographyarea under the curveCritical Illnessultraviolet spectroscopymid dose concentrationchemistryGlycopeptideMicrobiologyteicoplanin adultenterococcal infectionyoung adult Adultdrug clearanceYoung AdultTherapeutic indexPharmacokineticsInternal medicineAnti-Bacterial AgentmedicineHumanssteady statePharmacokineticsDosingAgedbusiness.industrydrug half lifeAntibioticrecommended drug doseAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical); Medicine (all)calibrationSurgerymulticenter studyTherapeutic drug monitoringdrug blood levelICU[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyfree plasma drug concentrationTeicoplaninbusinessmetabolism
researchProduct